https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 25 Aug 2021 11:22:48 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/tqxwndcaawu-ari-0001-cart19-cells-in-rr-b-all-with-isolated-extramedullary-disease/ Fri, 26 Feb 2021 14:08:22 +0000 http://13.40.107.223/video/tqxwndcaawu-ari-0001-cart19-cells-in-rr-b-all-with-isolated-extramedullary-disease/ Valentín Ortiz-Maldonado, MD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses the safety and efficacy outcomes of ARI-0001 CART19 cell therapy in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) with isolated extramedullary disease. Results show a good safety profile, the incidence of cytokine-release syndrome (CRS) was 40%, and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. Additionally, ARI-0001 therapy was able to achieve long-term remissions in this population of patients. This interview took place during the 3rd European CAR T-cell Meeting.

]]>